Abstract.
Oxaliplatin (Eloxatine) is a third-generation platinum compound which has shown a wide antitumour effect both in vitro and in vivo, a better safety profile than cisplatin and a lack of cross-resistance with cisplatin and carboplatin. In this scenario, oxaliplatin may represent an innovative and challenging drug extending the antitumour activity in diseases such as gastrointestinal cancer that are not usually sensitive to these coordination complexes. Oxaliplatin has a non-hydrolysable diaminocyclohexane (DACH) carrier ligand which is maintained in the final cytotoxic metabolites of the drug. Like cisplatin, oxaliplatin targets DNA producing mainly 1,2-GG intrastrand cross-links. The cellular and molecular aspects of the mechanism of action of oxaliplatin have not yet been fully elucidated. However, the intrinsic chemical and steric characteristics of the DACH-platinum adducts appear to contribute to the lack of cross-resistance with cisplatin. To date, mismatch repair and replicative bypass appear to be the processes most likely involved in differentiating the molecular responses to these agents.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received 15 March 2002; received after revision 13 May 2002; accepted 21 May 2002
RID="*"
ID="*"Corresponding author.
Rights and permissions
About this article
Cite this article
Di Francesco, A., Ruggiero, A. & Riccardi, R. Cellular and molecular aspects of drugs of the future: oxaliplatin. CMLS, Cell. Mol. Life Sci. 59, 1914–1927 (2002). https://doi.org/10.1007/PL00012514
Issue Date:
DOI: https://doi.org/10.1007/PL00012514